ESMO 2022 on a Randomized Phase II METEORA-II Trial: Metronomic Oral Vinorelbine + Cyclophosphamide & Capecitabine vs. Weekly Paclitaxel as 1L/2L Treatment for ER+/HER2- mBC

161 views
September 21, 2022
Comments 0
Login to view comments. Click here to Login